A new treatment for ankylosing spondylitis targets TRBV9+ T-cells and depletes T-lymphocytes using a cytotoxic antibody, directly attacking the cells primarily responsible for the disease. This innovative approach has resulted in a patient being in stable remission for four years.

A new treatment for ankylosing spondylitis targets TRBV9+ T-cells and depletes T-lymphocytes using a cytotoxic antibody, directly attacking the cells primarily responsible for the disease. This innovative approach has resulted in a patient being in stable remission for four years.